BRAF and neoplasm: Although BRAF mutations are no part of the WHO classification and not tumor specific, they are present in certain glioma subtypes with an increased rate and have potentially clinical implications since drugs are available that are active against some BRAF mutations (in particular the BRAF V600E mutation).